Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized ...

A year after stopping taking weight-loss drugs such as Ozempic and Wegovy, people regain—on average—60% of their lost weight. But beyond this, their regained weight plateaus, with individuals managing ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

Shifting the paradigm: Early identification of colorectal cancer with C the Signs clinical decision support. Survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as ...

Semaglutide, active ingredient in popular weight-loss drugs, including Ozempic and Wegovy, belongs to the class of medications known as GLP-1 receptor agonists.

This afternoon, we released financial results for the quarter and full year ended December 31, 2025, and recent corporate updates. The press release is available on the Investors section of our ...

The doravirine and islatravir pair could offer an alternative to INSTI-based treatment opt ...

OS of 8.9 months versus 5.8 months with trifluridine/tipiracil alone, supporting phase III ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

A key advantage of using RWD in a natural history study is gaining diverse and representative data. RWD covers broad patient populations, including those with comorbidities, various age groups, and ...